Food Allergy Counseling

Food Allergy Counseling
Sloane Miller, MFA, MSW, LMSW, Psychotherapist; Specialist in Food Allergy Management, Speaking At Mylan Specialty / EpiPen Event (© Noel Malcolm 2013)

Tuesday, February 23, 2016

Sanofi Update: SANOFI US TO RETURN AUVI-Q® (EPINEPHRINE INJECTION, USP) RIGHTS TO KALÉO

This afternoon, I heard from Sanofi US that they are returning the AUVI-Q® license to kaléo (originally Intelliject, the Edwards brothers who invented the AUVI-Q® product). kaléo will then decide how or if to get the product back to market.

***

Here's the press release below:

BRIDGEWATER, N.J., Feb. 23, 2016 /PRNewswire/ -- Sanofi announced today that the license and development agreement between Sanofi and kaléo, formerly Intelliject Inc., the developer of Auvi-Q® (epinephrine injection, USP), will terminate later this year. At that time, all U.S. and Canadian rights will be returned to kaléo. Sanofi is in discussions with kaléo on these terms and for an orderly transition plan. Kaléo will evaluate timing and options for bringing Auvi-Q back to market.

The decision to return rights for Auvi-Q aligns with Sanofi's ongoing transformation to focus on critical therapeutic areas in its five global business units: Diabetes & Cardiovascular, General Medicines & Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi US will complete the return and reimbursement process associated with the October 28, 2015, voluntary nationwide recall of Auvi-Q. For more information on the recall, please visit www.Auvi-Q.com.

***

I know many families relied upon this epinephrine auotinjector product. Please talk to your board certified medical health provider about additional options for epinephrine auotinjectors.

No comments: